SG156666A1 - Vaccines against japanese encephalitis virus and west nile virus - Google Patents

Vaccines against japanese encephalitis virus and west nile virus

Info

Publication number
SG156666A1
SG156666A1 SG200906992-3A SG2009069923A SG156666A1 SG 156666 A1 SG156666 A1 SG 156666A1 SG 2009069923 A SG2009069923 A SG 2009069923A SG 156666 A1 SG156666 A1 SG 156666A1
Authority
SG
Singapore
Prior art keywords
virus
west nile
japanese encephalitis
vaccines against
against japanese
Prior art date
Application number
SG200906992-3A
Other languages
English (en)
Inventor
Farshad Guirakhoo
Jian Liu
John A Catalan
Thomas P Monath
Konstantin V Pugachev
Original Assignee
Acambis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Inc filed Critical Acambis Inc
Publication of SG156666A1 publication Critical patent/SG156666A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG200906992-3A 2004-10-20 2005-10-19 Vaccines against japanese encephalitis virus and west nile virus SG156666A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62046604P 2004-10-20 2004-10-20
US62094804P 2004-10-21 2004-10-21
US67441505P 2005-04-24 2005-04-24
US67454605P 2005-04-25 2005-04-25
US71892305P 2005-09-19 2005-09-19

Publications (1)

Publication Number Publication Date
SG156666A1 true SG156666A1 (en) 2009-11-26

Family

ID=36203650

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200906992-3A SG156666A1 (en) 2004-10-20 2005-10-19 Vaccines against japanese encephalitis virus and west nile virus

Country Status (14)

Country Link
US (2) US8029802B2 (xx)
EP (1) EP1809325B1 (xx)
JP (1) JP4993301B2 (xx)
KR (1) KR101501162B1 (xx)
AU (1) AU2005295438B2 (xx)
CA (1) CA2584228C (xx)
EA (1) EA015907B1 (xx)
HK (1) HK1106723A1 (xx)
IL (1) IL182453A0 (xx)
MY (1) MY148075A (xx)
NO (1) NO20071924L (xx)
NZ (1) NZ584079A (xx)
SG (1) SG156666A1 (xx)
WO (1) WO2006044857A2 (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0210907A (pt) 2001-06-01 2004-12-21 Acambis Inc Vetores de flavivìrus quiméricos
NZ534159A (en) 2002-01-15 2007-03-30 Acambis Inc Vaccines comprising flaviviruses with one or more hinge region mutations that reduce viscerotropism of the flaviviruses
JP4683926B2 (ja) 2002-11-15 2011-05-18 サノフィ パスツール バイオロジクス カンパニー ウエストナイルウイルス・ワクチン
CA2584228C (en) 2004-10-20 2015-05-05 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
CA2605924A1 (en) 2005-04-24 2006-11-02 Acambis Inc. Recombinant flavivirus vaccines
AU2013204985B2 (en) * 2005-04-24 2016-01-28 Sanofi Pasteur Biologics, Llc Recombinant flavivirus vaccines
AU2008302276B2 (en) 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
JP5476544B2 (ja) 2006-09-29 2014-04-23 タケダ ワクチン，インコーポレイテッド ノロウイルスワクチン製剤
CA2668834C (en) 2006-11-07 2016-10-11 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization
CA2676775A1 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
US8715689B2 (en) * 2008-04-30 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
CN102177233B (zh) 2008-08-08 2015-04-15 莱戈赛特医药股份有限公司 用于增强交叉反应性的包含复合衣壳氨基酸序列的病毒样颗粒
US8961994B2 (en) * 2008-11-17 2015-02-24 Vgx Pharmaceuticals, Llc DNA constructs eliciting immune response against flavivirus and effective adjuvants
AU2010256845B2 (en) * 2009-06-01 2016-09-22 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CA2768997C (en) * 2009-07-31 2017-09-12 Xcellerex, Inc. High yield yellow fever virus strain with increased propagation in cells
BR112012024224A2 (pt) * 2010-03-24 2016-11-29 Arbovax Inc mutações da faixa de hospedeiro de flavivírus e seu uso.
CN101926989A (zh) * 2010-06-29 2010-12-29 西北农林科技大学 表达jev免疫原基因的重组减毒鼠伤寒沙门氏菌载体疫苗及其制备方法
WO2012003320A2 (en) * 2010-07-01 2012-01-05 Research Development Foundation Flavivirus host-range mutations and uses thereof
CA2841356C (en) 2011-07-11 2022-03-01 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
US9267114B2 (en) 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly
WO2014093182A1 (en) 2012-12-14 2014-06-19 Inviragen, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
AU2014281713A1 (en) 2013-06-21 2015-11-12 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
BR112015032388A8 (pt) 2013-06-26 2020-01-14 Univ North Carolina Chapel Hill glicoproteína e do vírus quimérico da dengue, seus usos, partícula de flavivírus, molécula de ácido nucleico isolado, e composições
WO2016079560A1 (en) * 2014-11-21 2016-05-26 Institut Pasteur A live and attenuated japanese encephalitis virus comprising a mutated m protein
WO2016106107A2 (en) 2014-12-22 2016-06-30 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
EA035921B1 (ru) * 2015-07-16 2020-08-31 Бхарат Байотек Интернэшнл Лимитед Вакцинные композиции для профилактики арбовирусных инфекций
CA3129482A1 (en) * 2019-03-28 2020-10-01 Nathalie PARDIGON A live and attenuated flavivirus comprising a mutated m protein

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US6676936B1 (en) * 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
ATE468858T1 (de) * 1997-02-28 2010-06-15 Acambis Inc Chimäre impfstoffe gegen flaviviren
US6589533B1 (en) 1997-09-18 2003-07-08 Research Development Foundation Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype
RU2208635C2 (ru) 1997-10-08 2003-07-20 ЗЕ ГАВЕРМЕНТ ОФ ЗЕ ЮНАЙТЕД СТАЙТС ОФ АМЕРИКА, репрезентед бай ЗЕ СЕКРЕТЕРИ, ДЕПАРТМЕНТ ОФ ХЕЛС ЭНД ХЬЮМЭН СЕРВАЙСЕЗ Днк-конструкт жизнеспособного химерного рекомбинантного флавивируса, вакцина против вируса клещевого энцефалита, способ предотвращения инфицирования млекопитающего вирусом клещевого энцефалита
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
WO2002081753A1 (en) 2001-04-04 2002-10-17 Advanced Research & Technology Institute Method for identifying and characterizing individual dna molecules
US20030180329A1 (en) 2002-01-15 2003-09-25 Monath Thomas P. Viral vaccine production method
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
NZ534159A (en) 2002-01-15 2007-03-30 Acambis Inc Vaccines comprising flaviviruses with one or more hinge region mutations that reduce viscerotropism of the flaviviruses
JP4683926B2 (ja) 2002-11-15 2011-05-18 サノフィ パスツール バイオロジクス カンパニー ウエストナイルウイルス・ワクチン
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
CA2584228C (en) 2004-10-20 2015-05-05 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
CA2605924A1 (en) 2005-04-24 2006-11-02 Acambis Inc. Recombinant flavivirus vaccines

Also Published As

Publication number Publication date
EP1809325A2 (en) 2007-07-25
US8029802B2 (en) 2011-10-04
MY148075A (en) 2013-02-28
WO2006044857A3 (en) 2006-08-10
EP1809325A4 (en) 2009-07-22
AU2005295438A1 (en) 2006-04-27
US8691550B2 (en) 2014-04-08
CA2584228A1 (en) 2006-04-27
EA200700904A1 (ru) 2007-12-28
JP4993301B2 (ja) 2012-08-08
EA015907B1 (ru) 2011-12-30
IL182453A0 (en) 2007-07-24
AU2005295438B2 (en) 2012-07-05
US20120201852A1 (en) 2012-08-09
NO20071924L (no) 2007-07-17
WO2006044857A2 (en) 2006-04-27
KR20070072597A (ko) 2007-07-04
EP1809325B1 (en) 2013-11-20
HK1106723A1 (en) 2008-03-20
US20070269458A1 (en) 2007-11-22
JP2008520187A (ja) 2008-06-19
CA2584228C (en) 2015-05-05
KR101501162B1 (ko) 2015-03-16
NZ584079A (en) 2011-10-28

Similar Documents

Publication Publication Date Title
SG156666A1 (en) Vaccines against japanese encephalitis virus and west nile virus
WO2005082020A8 (en) Flavivirus vaccines
HK1083192A1 (en) West nile virus vaccine
WO2003101397A3 (en) Tetravalent dengue vaccines
WO2003103571A3 (en) VACCINES AGAINST FLAVIVIRUSES
RS20060320A (xx) Supstituisani indazol-o-glukozidi
SG130189A1 (en) Substituted indole-o-glucosides
UA86042C2 (xx) Заміщені індазол-о-глюкозиди$замещенные индазол-о-глюкозиды
WO2005042767A3 (en) Compositions and methods for detecting severe acute respiratory syndrome coronavirus
WO2007030810A3 (en) Multiparameter whole blood monitor and method
SG165155A1 (en) Novel flavivirus antigens
UA103316C2 (uk) Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
TW200738270A (en) Method of treating depression using a TNFα antibody
TW200732349A (en) Anti-OX40L antibodies and methods using same
WO2006076003A3 (en) Vaccinia virus strains
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
WO2006026470A3 (en) Hiv immunostimulatory compositions
EP1794329A4 (en) ISOLATES OF PORCINE RESPIRATORY DYSGENESIS SYNDROME (SDRP), AND METHODS OF USE
ATE434639T1 (de) Wässrige dispersionen von silikon-polyether- blockcopolymeren
GB2435590A (en) An interleaver and associated methods
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2004091524A3 (en) Respiratory virus vaccines
WO2006029300A3 (en) Flavivirus variants having phenotypic variation and immunogenic compositions thereof
WO2007047916A3 (en) Multiclade hiv vaccines
WO2004009764A3 (en) Methods and compositions concerning altered yellow fever virus strains